Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Nov 17 - Nov 22
Chang M-L, Liao L-J, Lin J-H, Liu Z-H, Hsu Y-T, Lee T-M
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
SURMOUNT-1 (tirzepatide, 72 weeks): Discontinuation due to AEs: 4.3% (5 mg), 7.1% (10 mg), 6.2% (15 mg) vs 2.6% placebo Key characteristics: GI events occur primarily during dose escalation The GIP component does not appear to add substantial GI burden beyond GLP-1 effects Pooled SURMOUNT-1 to -4 analysis showed treatment discontinuation due to GI AEs ranged from 1.0% to 10.5% Retatrutide# Retatrutide adds glucagon receptor agonism to GLP-1 and GIP, creating a triple agonist
People with naturally sensitive stomachs, a history of IBS, or a tendency toward loose stools may feel these effects more strongly
Your plan should be individualized dose, timing, and stacking options vary based on goals and history
